Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. - Bosaeed M; Balkhy HH; Almaziad S; Aljami HA; Alhatmi H; Alanazi H; Alahmadi M; Jawhary A; Alenazi MW; Almasoud A; Alanazi R; Bittaye M; et al. (The Lancet. Microbe, 2022)